Kaul N, Gupta V, Bhardwaj S, Dogra D, Dogra N, 2016. A new focus of cutaneous leishmaniasis in Jammu division of Jammu and Kashmir State, India. Indian J Dermatol Venereol Leprol 82: 145–150.
Aara N, Khandelwal K, Bumb RA, Mehta RD, Ghiya BC, Jakhar R, Dodd C, Salotra P, Satoskar AR, 2013. Clinco-epidemiologic study of cutaneous leishmaniasis in Bikaner, Rajasthan, India. Am J Trop Med Hyg 89: 111–115.
Rajni E, Ghiya BC, Singh S, Shankar P, Swami T, Jadon DS, Negi SR, Malik M, Khatri PK, 2019. Cutaneous leishmaniasis in Bikaner, India: clinicoepidemiological profile; parasite identification using conventional, molecular methods and CL Detect™ rapid test, a new Food and Drug Administration-approved test. Trop Parasitol 9: 115–123.
Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J, Arenas R, 2017. Leishmaniasis: a review. F1000Research 6: 750.
Daulatabad D, Singal A, Dhawan A, Pandhi D, Sharma S, 2015. Mucocutaneous leishmaniasis caused by Leishmania donovani infection in an Indian man. Int J Dermatol 54: 680–684.
Pulimood SA, Rupali P, Ajjampur SSR, Thomas M, Mehrotra S, Sundar S, 2012. Atypical mucocutaneous involvement with Leishmania donovani. Natl Med J India 25: 148–150.
Sethuraman G, Sharma VK, Salotra P, 2008. Indian mucosal leishmaniasis due to Leishmania donovani infection. N Engl J Med 58: 313–315.
World Health Organization, 2019. Leishmaniasis. Available at: https://www.who.int/en/news-room/fact-sheets/detail/leishmaniasis. Accessed on Feb 19, 2019.
Bhunia GS, Kesari S, Chatterjee N, Kumar V, Das P, 2013. The burden of visceral leishmaniasis in India: challenges in using remote sensing and GIS to understand and control. Int Sch Res Not 2013: 675846.
Stauch A, Sarkar RR, Picado A, Ostyn B, Sundar S, Rijal S, Boelaert M, Dujardin JC, Duerr HP, 2011. Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. PLoS Negl Trop Dis 5: e1405.
Ramesh V, Kaushal H, Mishra AK, Singh R, Salotra P, 2015. Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study. BMC Public Health 15: 1092.
Christian Medical College, 2019. Facts and Figures 2017 - 2018.pdf. Available at: https://www.cmch-vellore.edu/sites/common/Facts%20&%20Figures%202017%20-%202018.pdf. Accessed April 5, 2019.
World Health Organization, 2010. Control of the Leishmaniases. Report of a WHO Expert Committee. WHO Technical Report Series, Vol. 949. Geneva, Switzerland: WHO.
Scorza BM, Carvalho EM, Wilson ME, 2017. Cutaneous manifestations of human and murine leishmaniasis. Int J Mol Sci 18: 1296.
Choi CM, Lerner EA, 2006. Leishmaniasis as an emerging infection. J Investig Dermatol Symp Proc 6: 175–182.
Zijlstra EE, el-Hassan AM, Ismael A, 1995. Endemic kala-azar in eastern Sudan: post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg 52: 299–305.
Lockard RD, Wilson ME, Rodríguez NE, 2019. Sex-related differences in immune response and symptomatic manifestations to infection with Leishmania species. J Immunol Res 2019: 4103819.
Varghese L, Laxmanan S, Varghese GM, 2020. Mucosal leishmaniasis due to Leishmania donovani—a rare presentation. Ear Nose Throat J, doi:10.1177/0145561320952186.
David CV, Craft N, 2009. Cutaneous and mucocutaneous leishmaniasis. Dermatol Ther 22: 491–502.
Das VNR, Siddiqui NA, Pal B, Lal CS, Verma N, Kumar A, Verma RB, Kumar D, Das P, Panday K, 2017. To evaluate efficacy and safety of amphotericin B in two different doses in the treatment of post kala-azar dermal leishmaniasis (PKDL). PLoS One 12: e0174497.
Thakur L, Singh KK, Shanker V, Negi A, Jain A, Matlashewski G, Jain M, 2018. Atypical leishmaniasis: a global perspective with emphasis on the Indian subcontinent. PLoS Negl Trop Dis 12: e0006659.
Siriwardana Y, Deepachandi B, Gunasekara C, Warnasooriya W, Karunaweera ND, 2019. Leishmania donovani induced cutaneous leishmaniasis: an insight into atypical clinical variants in Sri Lanka. J Trop Med 2019: 4538597.
Pires CAA, Pereira NG, Moreira AG, Sena JMC, Costa CCC, Bastos TDS, Rodrigues FDN, Faustino EP, da Silva JRC, Santos MAL, 2019. Cutaneous leishmaniasis mimicking cutaneous lymphoma. IDCases 17: e00580.
Yangzom T, Cruz I, Bern C, Argaw D, den Boer M, Vélez ID, Bhattacharya SK, Molina R, Alvar J, 2012. Endemic transmission of visceral leishmaniasis in Bhutan. Am J Trop Med Hyg 87: 1028–1037.
WHO, 2020. Global leishmaniasis surveillance, 2017–2018, and first report on 5 additional indicators. Weekly Epidemiol Rec 95: 265–280.
Kumari A, Balai M, Gupta LK, Khare AK, Mittal AK, Mehta S, 2018. Diffuse cutaneous leishmaniasis in an immunocompromised patient resembling histoid Hansen’s disease. Indian Dermatol Online J 9: 452–454.
Chaudhary RG, Bilimoria FE, Katare SK, 2008. Diffuse cutaneous leishmaniasis: co-infection with human immunodeficiency virus (HIV). Indian J Dermatol Venereol Leprol 74: 641–643.
Meireles CB, Maia LC, Soares GC, Teodoro IPP, Gadelha MDSV, da Silva CGL, de Lima MAP, 2017. Atypical presentations of cutaneous leishmaniasis: a systematic review. Acta Trop 172: 240–254.
Kumar NP, Srinivasan R, Anish TS, Nandakumar G, Jambulingam P, 2015. Cutaneous leishmaniasis caused by Leishmania donovani in the tribal population of the Agasthyamala biosphere reserve forest, western ghats, Kerala, India. J Med Microbiol 64: 157–163.
Nawaratna SSK, Weilgama DJ, Wijekoon CJ, Dissanayake M, Rajapaksha K, 2007. Cutaneous leishmaniasis, Sri Lanka. Emerg Infect Dis 13: 1068–1070.
Leishmaniasis is endemic in the Indian subcontinent with predominance of visceral leishmaniasis (VL) due to Leishmania donovani. Cutaneous leishmaniasis (CL) is uncommon, and mucocutaneous leishmaniasis (MCL) is rarely reported in this region. Recent reports reveal a changing epidemiology and atypical manifestations. A retrospective study of 52 suspected cases with cutaneous and mucosal involvement seen from January 2008 to December 2018 in a tertiary care setting in a non-endemic state in southern India is reported. Twelve patients were confirmed to have leishmaniasis; seven had MCL, two had CL, and three had post-kala-azar dermal leishmaniasis (PKDL). All cases were male, with a median age of 41.5 years (interquartile range, 30–55.5 years), and the median duration of the disease was 6 years (interquartile range, 1–9.5 years). Patients with MCL had mucosal involvement including destructive ulcero-proliferative lesions due to delayed diagnosis; none had a history of travel to countries endemic for MCL and all were attributable to L. donovani species. On the other hand, Leishmania major which was the causative species in both CL patients was associated with travel to the Middle East. Patients with PKDL presented with multiple plaques and hypopigmented patches; one had concomitant VL and all were from endemic areas. Hitherto uncommon MCL, caused by potentially atypical variants of L. donovani, has emerged as a new manifestation of leishmaniasis in this region. A high index of suspicion based on lesions seen and history of travel combined with PCR-based diagnostics are required to confirm diagnosis for the various skin manifestations of leishmaniasis.
Authors’ addresses: Santhi John Tharakan, Dincy Peter CV, and Susanne Pulimood, Department of Dermatology, Christian Medical College, Vellore, India, E-mails: shantijohnt15@gmail.com, dincypeter@gmail.com, and sapulimood@cmcvellore.ac.in. Rajiv Karthik and Priscilla Rupali, Infectious Diseases, Christian Medical College, Vellore, India, E-mails: rajiv@cmcvellore.ac.in and prisci@cmcvellore.ac.in. Vedantam Rupa, ENT, Christian Medical College, Vellore, India, E-mail: rupavedantam@cmcvellore.ac.in. Winsley Rose, Pediatric Infectious Diseases, Christian Medical College, Vellore, India, E-mail: winsleyrose@cmcvellore.ac.in. Meera Thomas, Pathology, Christian Medical College, Vellore, India, E-mail: meerathomas@cmcvellore.ac.in. Malathi Manuel and Sitara Swarna Rao Ajjampur, Division of Gastrointestinal Sciences, The Wellcome Trust Research Laboratory, Christian Medical College, Vellore, India, E-mails: malathimanuel25@gmail.com and sitararao@cmcvellore.ac.in.